Nature of Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended
	Mar. 09, 2023	Mar. 10, 2022	Nov. 09, 2020	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from Sale of Equity Method Investments		$ 130,000
Net income				$ (28,844)	$ 92,105
Loss from operations				27,511	$ 37,618
Accumulated deficit				$ 457,981		$ 429,137
Oxford Biomedica Plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Upfront Payment Received		130,000
Proceeds from Sale of Equity Method Investments		$ 50,000
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net proceed from issuance of common stock	$ 250,000
Private Placement
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Share			5,000,000
Shares issued price per share			$ 12.00
Net proceed from issuance of common stock			$ 60,000
ATM
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of common stock, net of discounts and issuance costs, Share				0
Proceeds through future financings				$ 75,000
ATM | Oxford Biomedica Plc
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction		80.00%
ATM | Homology Member
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Sale of Stock, Percentage of Ownership after Transaction		20.00%
ATM | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds through future financings	$ 75,000